News

Press Release

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

"Vibrant China Research Tour" Visits Mabwell in Shanghai, Spotlighting Innovative Practices in Biopharmaceutical Source Innovation

Mabwell's Adalimumab Included in the 2026 National Essential Drug List

2026 WOC | Mabwell Presents Clinical Results of Anti-VEGF Antibody 9MW0211 as Oral Presentation

Mabwell Receives IND Clearance from NMPA for 9MW5211 for Multiple Sclerosis

Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

Mabwell's Subsidiary Myvision Enters Strategic Cooperation with VivaVision

EHA 2026 | Mabwell Presents Latest Clinical Results of Novel Anti-TMPRSS6 Monoclonal Antibody 9MW3011

Mabwell’s LILRB4/CD3 targeting TCE Bispecific Antibody 6MW5311 Receives FDA Clearance for Clinical Trial Application

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

1 2 3 4 Next